Company news
Biophytis Sa (EURONEXT:ALBPS) news
Biophytis Sa news releases on 6ix. Latest, Sep 11, 2026: Biophytis S A : ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL…
Press releases & updates
Biophytis S A : ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
September 11, 2026
Biophytis S A : to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity
September 9, 2026
Biophytis S A : strengthens its financial position and extends its cash runway into Q1 2027
August 31, 2026
Biophytis S A : PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
August 3, 2026
Biophytis S A : INFORMATION ON ANNUAL FINANCIAL STATEMENTS
April 29, 2026
Biophytis S A : PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
March 13, 2026
Biophytis S A : LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
March 12, 2026
Biophytis S A : ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT
March 11, 2026
Biophytis S A : increases to €2 million the ceiling of its bond facility with Hexagon Capital Fund
February 27, 2026
Biophytis S A : conclut un accord stratégique en Asie et sécurise 20 M$ pour le lancement de sa Phase 3 dans la sarcopénie
January 28, 2026
Biophytis S A : enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
January 28, 2026
Biophytis S A : participe à la JP Morgan Healthcare Conference et au Biomed Forum
January 12, 2026
Biophytis S A : to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
January 12, 2026
Biophytis S A : All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 31% of the shareholders present or…
November 13, 2025
Biophytis S A : Reports First-Half 2025 Results and Provides Strategic Update
October 30, 2025
Biophytis S A : dévoile les résultats du premier semestre 2025 et fait le point sur sa stratégie
October 30, 2025
Biophytis S A : and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia
October 13, 2025
Biophytis S A : to Participate in Four Key Events in Q4 2025
September 30, 2025
Biophytis S A : annonce sa participation à quatre événements clés au cours du 4ème trimestre 2025
September 30, 2025
Biophytis S A : Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
September 15, 2025
Biophytis S A : obtient un financement public au Brésil pour l’essai de Phase 2 dans l’obésité et signe des accords avec des centres cliniques locaux de premier plan
September 15, 2025
Biophytis S A : unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
September 11, 2025
Biophytis S A : obtient l'autorisation de l'EMA pour le lancement de son étude clinique de phase 2 dans l’obésité
September 3, 2025
Biophytis S A : obtains EMA authorization to launch its Phase 2 clinical trial in obesity
September 3, 2025